203 related articles for article (PubMed ID: 21606531)
21. Safety and immunogenicity of an influenza vaccine A/H5N1 (A/Vietnam/1194/2004) when coadministered with a heat-labile enterotoxin (LT) adjuvant patch.
Glenn GM; Thomas DN; Poffenberger KL; Flyer DC; Ellingsworth LR; Andersen BH; Frech SA
Vaccine; 2009 Dec; 27 Suppl 6():G60-6. PubMed ID: 20006142
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of two different doses of a Vero cell-derived, whole virus clade 2 H5N1 (A/Indonesia/05/2005) influenza vaccine.
Tambyah PA; Wilder-Smith A; Pavlova BG; Barrett PN; Oh HM; Hui DS; Yuen KY; Fritsch S; Aichinger G; Loew-Baselli A; van der Velden M; Maritsch F; Kistner O; Ehrlich HJ
Vaccine; 2012 Jan; 30(2):329-35. PubMed ID: 22080174
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.
Madan A; Segall N; Ferguson M; Frenette L; Kroll R; Friel D; Soni J; Li P; Innis BL; Schuind A
J Infect Dis; 2016 Dec; 214(11):1717-1727. PubMed ID: 27609809
[TBL] [Abstract][Full Text] [Related]
24. A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03.
Naruse T; Fukuda T; Tanabe T; Ichikawa M; Oda Y; Tochihara S; Kimachi K; Kino Y; Ueda K
Vaccine; 2015 Nov; 33(45):6078-84. PubMed ID: 26409141
[TBL] [Abstract][Full Text] [Related]
25. An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults.
Gillard P; Caplanusi A; Knuf M; Roman F; Walravens K; Moris P; Dramé M; Schwarz TF
Influenza Other Respir Viruses; 2013 Jan; 7(1):55-65. PubMed ID: 22405557
[TBL] [Abstract][Full Text] [Related]
26. Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial.
Howard LM; Hoek KL; Goll JB; Samir P; Galassie A; Allos TM; Niu X; Gordy LE; Creech CB; Prasad N; Jensen TL; Hill H; Levy SE; Joyce S; Link AJ; Edwards KM
PLoS One; 2017; 12(1):e0167488. PubMed ID: 28099485
[TBL] [Abstract][Full Text] [Related]
27. Cross-clade immunogenicity and safety of an AS03A-adjuvanted prepandemic H5N1 influenza vaccine in Hong Kong.
Chu DW; Kwong AS; Tsui WW; Wang JH; Ngai CK; Wan PK; Ong G; Tang HW; Roman F; Dram M; Bock HL
Hong Kong Med J; 2011 Feb; 17(1):39-46. PubMed ID: 21282825
[TBL] [Abstract][Full Text] [Related]
28. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
[TBL] [Abstract][Full Text] [Related]
29. A Phase 2/3 double blinded, randomized, placebo-controlled study in healthy adult participants in Vietnam to examine the safety and immunogenicity of an inactivated whole virion, alum adjuvanted, A(H5N1) influenza vaccine (IVACFLU-A/H5N1).
Duong TN; Thiem VD; Anh DD; Cuong NP; Thang TC; Huong VM; Chien VC; Phuong NTL; Montomoli E; Holt R; Scorza FB; Flores J; Tewari T
Vaccine; 2020 Feb; 38(6):1541-1550. PubMed ID: 31812464
[TBL] [Abstract][Full Text] [Related]
30. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.
Leroux-Roels I; Borkowski A; Vanwolleghem T; Dramé M; Clement F; Hons E; Devaster JM; Leroux-Roels G
Lancet; 2007 Aug; 370(9587):580-9. PubMed ID: 17707753
[TBL] [Abstract][Full Text] [Related]
31. The safety and immunogenicity of a MF59-adjuvanted H5N1 prepandemic influenza vaccine in healthy adults primed with homologous or heterologous H5N1 vaccines: an observational study.
Wei SH; Liu MT; Tsai YC; Liao CH; Chen CM; Wang WY; Huang YL; Chang FY; Chou P
BMC Infect Dis; 2014 Nov; 14():587. PubMed ID: 25394941
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of influenza A(H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).
Oshansky CM; Zhou J; Gao Y; Schweinle JE; Biscardi K; DeBeauchamp J; Pavetto C; Wollish A; ; Webby RJ; Cioce V; Donis RO; Bright RA
Vaccine; 2019 Jan; 37(3):435-443. PubMed ID: 30553570
[TBL] [Abstract][Full Text] [Related]
33. Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects.
Chanthavanich P; Anderson E; Kerdpanich P; Bulitta M; Kanesa-Thasan N; Hohenboken M
Pediatr Infect Dis J; 2019 Jul; 38(7):757-764. PubMed ID: 31194712
[TBL] [Abstract][Full Text] [Related]
34. Cross-clade immunogenicity and antigen-sparing with an AS03(A)-adjuvanted prepandemic influenza vaccine in a Thai population.
Thongcharoen P; Auewarakul P; Hutagalung Y; Ong G; Gillard P; Drame M; Bock HL
J Med Assoc Thai; 2011 Aug; 94(8):916-26. PubMed ID: 21863672
[TBL] [Abstract][Full Text] [Related]
35. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
[TBL] [Abstract][Full Text] [Related]
36. Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of age.
Nolan T; Izurieta P; Lee BW; Chan PC; Marshall H; Booy R; Drame M; Vaughn DW
J Infect Dis; 2014 Dec; 210(11):1800-10. PubMed ID: 24973461
[TBL] [Abstract][Full Text] [Related]
37. Safety and immunogenicity of a split-virion AS03A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults.
Yang PC; Yu CJ; Chang SC; Hsieh SM; Drame M; Walravens K; Roman F; Gillard P
J Formos Med Assoc; 2012 Jun; 111(6):333-9. PubMed ID: 22748624
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity and safety of AS03A-adjuvanted H5N1 influenza vaccine prepared from bulk antigen after stockpiling for 4 years.
Godeaux O; Izurieta P; Madariaga M; Dramé M; Li P; Vaughn DW
Vaccine; 2015 Apr; 33(18):2189-95. PubMed ID: 25090645
[TBL] [Abstract][Full Text] [Related]
39. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.
Schwarz TF; Horacek T; Knuf M; Damman HG; Roman F; Dramé M; Gillard P; Jilg W
Vaccine; 2009 Oct; 27(45):6284-90. PubMed ID: 19856521
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of an AS03(A)-adjuvanted H5N1 influenza vaccine in a Taiwanese population.
Hwang SJ; Chang SC; Yu CJ; Chan YJ; Chen TJ; Hsieh SL; Lai HY; Lin MH; Liu JY; Ong G; Roman F; Dramé M; Bock HL; Yang PC
J Formos Med Assoc; 2011 Dec; 110(12):780-6. PubMed ID: 22248833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
